the state of the s

10

CLAIMS

1. The use of a compound of the formula I:

$$R^{2}$$
 R^{1}
 R^{1}
 R^{4}
 R^{5}

5

10

15

(I)

wherein

X is

-C(O)-, -C(S)-, -C=NOH, or -CH(R⁷)- wherein R⁷ is hydrogen, hydroxy, C_{1-7} alkoxy, -OR⁸ or -NR⁸R⁹ (wherein R⁸ is a group -Y¹R¹⁰ (wherein Y¹ is a direct bond, -C(O)-, -C(S)-, -S-, -C(O)O-, -C(O)NR¹¹-, -SO₂- or -SO₂NR¹²- (wherein R¹¹ and R¹², which may be the same or different, each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R¹⁰ is selected from one of the following nine groups:

1) hydrogen, C_{1.7}alkyl, C_{3.7}cycloalkyl, C_{1.4}alkylY⁸C_{1.4}alkyl wherein Y⁸ is as defined herein, or phenyl,

(which alkyl, cycloalkyl, alkylY⁸alkyl or phenyl group may bear one or more substituents selected from:

halogeno, amino, $C_{1\rightarrow}$ alkylamino, di $(C_{1\rightarrow}$ alkyl)amino, hydroxy, carboxy, carbamoyl, $C_{1\rightarrow}$ alkoxy, $C_{1\rightarrow}$ alkylsulphanyl, $C_{1\rightarrow}$ alkylsulphonyl, $C_{1\rightarrow}$ alkoxycarbonylamino, $C_{1\cdot}$ alkanoyl, phenyl, nitro, sulphate, phosphate,

Z¹ (wherein Z¹ represents a 5-6 membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, $C_{1,4}$ alkyl, $C_{1,4}$ hydroxyalkyl, $C_{1,4}$ alkoxy, $C_{1,4}$ aminoalkyl, $C_{1,7}$ alkanoyl, cyano $C_{1,4}$ alkyl, $C_{1,4}$ alkoxy $C_{1,4}$ alkyl, $C_{1,4}$ alkylsulphonyl $C_{1,4}$ alkyl and Z^2 (wherein Z^2 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms,

20

selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} alkyl, C_{1-4} alkyl, C_{1-4} alkyl and C_{1-4} alkylsulphonyl C_{1-4} alkyl)),

10

5

T. 45

graph and a series of the seri

C₁₋₄alkylZ¹ (wherein Z¹ is as defined herein), and a group -Y²R¹³ (wherein Y² is -NR¹⁴C(O)- or -O-C(O)- (wherein R¹⁴ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹³ is C₁₋₇alkyl, C₃₋₇cycloalkyl or a group R¹⁵ wherein R¹⁵ is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, cyano, -CONR¹⁶R¹⁷ and -NR¹⁸COR¹⁹ (wherein R¹⁶, R¹⁷, R¹⁸ and R¹⁹, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂. ³alkyl)));

- 2) R¹⁵ wherein R¹⁵ is as defined herein;
- 3) C_{2,7}alkenylR¹⁵ (wherein R¹⁵ is as defined herein);
- 4) C_{3.7}alkynylR¹⁵ (wherein R¹⁵ is as defined herein));
- 5) Z¹ (wherein Z¹ is as defined herein);
- 6) C₁₋₇alkylZ¹ (wherein Z¹ is as defined herein);
- 7) $C_{1.7}$ alkylY⁸Z¹ (wherein Z¹ is as defined herein and Y⁸ is -C(O)-, -NR⁵⁹C(O)-, -NR⁵⁹C(O)C₁. 4alkyl-, -C(O)NR⁶⁰- or -C(O)NR⁶⁰C_{1.4}alkyl-, (wherein R⁵⁹ and R⁶⁰, which may be the same or different, each represents hydrogen, C_{1.3}alkyl, C_{1.3}hydroxyalkyl or C_{1.3}alkoxyC_{2.3}alkyl));
- 8) (C₁₋₇alkyl)_cY⁹Z³ (wherein c is 0 or I, Z³ is an amino acid group and Y⁹ is a direct bond, C(O)- or -NR⁶¹- (wherein R⁶¹ is hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl)); and
 9) C₁₋₇alkylR¹⁵ (wherein R¹⁵ is as defined herein);
 and R⁹ is hydrogen, C₁₋₇alkyl or C₃₋₇cycloalkyl, which alkyl or cycloalkyl group may bear one or more substituents selected from C₁₋₄alkoxy and phenyl);

30

R¹, R² and R³ are each independently

and a series are the series are the

5

10

15

20

25

30

hydrogen, PO₃H₂, sulphate, C₃₋₇cycloalkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₁₋₇alkanoyl, a group R²⁰C_{1,7}alkyl (wherein R²⁰ is phenyl which may bear one or more substituents selected from C_{1.7} alkyl, C14alkoxy, C14aminoalkyl and C14hydroxyalkoxy), C1.7alkyl or C1.7alkylsulphonyl (which alkyl or alkylsulphonyl group may bear one or more substituents selected from: halogeno, amino, C₁₄alkylamino, di(C₁₄alkyl)amino, hydroxy, C₁₄alkoxy, C₁ ₄alkylsulphanyl, C_{1,4}alkylsulphonyl, C_{1,4}alkoxycarbonylamino, C_{1,4}alkanoyl, carboxy, phenyl, nitro, sulphate, phosphate and a group -Y²R²¹ (wherein Y² is -NR²²C(O)- or -O-C(O)- (wherein R²² represents hydrogen, C₁₋₁alkyl or C₁₋₁alkoxyC₂₋₃alkyl) and R²¹ is C₁. ₂alkyl, C₃₋₂cycloalkyl or a group R²³ wherein R²³ is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₁ haloalkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₁ Ahydroxyalkoxy, carboxy, cyano, -CONR²⁴R²⁵ and -NR²⁶COR²⁷ (wherein R²⁴, R²⁵, R²⁶ and R²⁷, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁. alkoxyC23alkyl)));

 R^4 , R^5 and R^6 are each independently selected from: hydrogen, -OPO $_3H_2$, phosphonate, cyano, halogeno, nitro, amino, carboxy, carbamoyl,

hydroxy, C_{1.7}alkoxy, C_{1.7}alkanoyl, C_{1.7}thioalkoxy, C_{1.7}alkyl,

with the proviso that at least two of R¹, R² and R³ are C_{1.7}alkyl;

(which alkyl group may bear one or more substituents selected from: halogeno, amino, C_{14} alkylamino, di(C_{14} alkyl)amino, hydroxy, C_{14} alkoxy, C_{14} alkoxy, C_{14} alkylsulphanyl, C_{14} alkylsulphanyl, C_{14} alkoxycarbonylamino, C_{14} alkanoyl, carboxy, phenyl, sulphate, phosphate and a group -Y³R²⁸ (wherein Y³ is -NR²⁹C(O)- or -O-C(O)- (wherein R²⁹ represents hydrogen, C_{13} alkyl or C_{13} alkoxy C_{23} alkyl) and R^{28} is C_{14} alkyl, C_{34} cycloalkyl or a group R^{30} wherein R^{30} is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C_{14} alkyl, C_{14} alkoxy, C_{14} hydroxyalkyl, C_{14} aminoalkyl, C_{14} alkylamino, C_{14} alkylamino, C_{14} ahydroxyalkoxy, carboxy, cyano, -CONR³¹R³² and -NR³¹COR³² (wherein R³¹, R³², R³³ and

 R^{34} , which may be the same or different, each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl))), and

a group -Y4R35

5

10

15

20

25

30

(wherein Y⁴ is -C(O)-, -OC(O)-, -O-, -SO-, -SO₂-, -OSO₂-, -NR³⁶-, -C₁₋₄alkylNR³⁶-, -C₁₋₄alkylC(O)-, -NR³⁷C(O)-, -OC(O)O-, -C(O)NR³⁸- or -NR³⁹C(O)O- (wherein R³⁶, R³⁷, R³⁸ and R³⁹, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁₋₄alkoxyC₂₋₃alkyl) and

 R^{35} is a sugar moiety, a mono-peptide, a di-peptide, a tri-peptide, a tetra-peptide, sulphate, hydroxy, amino, C_{1-7} alkyl, C_{1-7} alkoxy, C_{1-7} alkanoyl, C_{1-7} alkylamino, di(C_{1-7} alkylamino, amino C_{1-7} alkylamino, C_{1-7} alkylamino, C_{1-7} alkylamino, C_{1-7} alkylamino, C_{1-7} alkylamino, C_{1-7} alkylphosphonate, C_{1-7} alkylphosphonate, C_{1-7} alkylcarbamoyl C_{1-7} alkyl,

(which alkyl, alkoxy, alkanoyl, alkylamino, dialkylamino, aminoalkylamino, alkylamino, alkylaminoalkylamino, alkanoylaminoalkyl, dialkylaminoalkylamino, alkylphosphate, alkylphosphonate or alkylcarbamoylalkyl, may bear one or more substituents selected from:

halogeno, amino, $C_{1,4}$ alkylamino, di($C_{1,4}$ alkyl)amino, hydroxy, $C_{1,4}$ hydroxyalkyl, $C_{1,4}$ alkoxy, $C_{1,4}$ alkylsulphanyl, $C_{1,4}$ alkylsulphonyl, $C_{1,4}$ alkoxycarbonylamino, $C_{1,4}$ alkoxy, carboxy, phenyl, nitro, sulphate, phosphate and a group $-Y^5R^{40}$ (wherein Y^5 is $-NR^{41}C(O)$ -, $-C(O)NR^{42}$ -, -C(O)-O- or -O--C(O)- (wherein R^{41} and R^{42} which may be the same or different each represents hydrogen, $C_{1,3}$ alkyl or $C_{1,3}$ alkoxy $C_{2,3}$ alkyl) and R^{40} is $C_{1,7}$ alkyl, $C_{3,7}$ cycloalkyl, carboxy $C_{1,7}$ alkyl or a group R^{43} wherein R^{43} is a phenyl group, a benzyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl, benzyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, $C_{1,4}$ alkyl, $C_{1,4}$ haloalkyl, $C_{1,4}$ alkoxy, $C_{1,4}$ hydroxyalkyl, $C_{1,4}$ aminoalkyl, $C_{1,4}$ alkylamino, $C_{1,4}$ hydroxyalkoxy, carboxy, cyano, $-CONR^{44}R^{45}$ and $-NR^{46}COR^{47}$ (wherein R^{44} , R^{45} , R^{46} and R^{47} , which may be the same or different, each represents hydrogen, $C_{1,3}$ alkyl or $C_{1,3}$ alkoxy $C_{2,3}$ alkyl))),

R⁴⁸ (wherein R⁴⁸ is a phenyl group, a benzyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected

10

15

20

25

30

- 119 -

independently from O, N and S, which phenyl, benzyl or aromatic heterocyclic group may bear one or more substituents selected from

hydroxy, nitro, halogeno, amino, C₁₄alkyl, C₁₄haloalkyl, C₁₄alkoxy, C₁₄hydroxyalkyl, C_{1.4}aminoalkyl, C_{1.4}alkylamino, di(C_{1.4}alkyl)amino, di(C_{1.4}alkyl)aminoC_{1.4}alkyl, di(C_{1.4} hydroxyalkyl)aminoC_{1.4}alkyl, di(C_{1.4}aminoalkyl)aminoC_{1.4}alkyl, C_{1.4}hydroxyalkoxy, carboxy, C1.4carboxyalkyl, phenyl, cyano, -CONR49R50, -NR51COR52 (wherein R49, R50, R⁵¹ and R⁵², which may be the same or different, each represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and C_{1.4}alkylR⁵³ (wherein R⁵³ is as defined herein),

C_{1.7}alkylR⁴⁸ (wherein R⁴⁸ is as defined herein),

R⁵³ (wherein R⁵³ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, C₁₄alkyl, C₁₄hydroxyalkyl, C₁₄alkoxy, C₁₄carboxyalkyl, C₁ aminoalkyl, di(C_{1.4}alkyl)aminoC_{1.4}alkyl, C_{1.4}alkoxyC_{1.4}alkyl, C_{1.4}alkylsulphonylC_{1.4} alkyl and R⁵⁴ (wherein R⁵⁴ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁. alkyl and C_alkylsulphonylC_alkyl)), or

(CH₂)₂Y⁶(CH₂)₆R⁵³ (wherein R⁵³ is as defined herein, a is 0, or an integer 1-4, b is 0 or an integer 1-4 and Y⁶ represents a direct bond, -O-, -C(O)-, -NR⁵⁵-, -NR⁵⁶C(O)- or -C(O)NR⁵⁷- (wherein R⁵⁵, R⁵⁶, and R⁵⁷, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and wherein one or more of the (CH₂)_a or (CH₂), groups may bear one or more substituents selected from hydroxy, amino and halogeno));

with the proviso that R5 is not hydroxy, alkoxy, substituted alkoxy (wherein R5 is Y4R35 and Y4 is -O- and R35 is C1.7alkyl bearing one or more substituents selected from the list given herein), -OPO₃H₂, -O-C_{1,7}alkanoyl or benzyloxy;

or a salt thereof, a pharmaceutically acceptable salt thereof, a solvate or hydrate thereof, or a prodrug thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in warm-blooded animals such as humans.

15

20

25

2. A compound of the formula IIa:

$$R^2$$
 R^3
 X
 R^4
 R^4
 R^6
 R^5

(IIa)

5 wherein

X is

-C(O)-, -C(S)-, -C=NOH, or -CH(R⁷)- wherein R⁷ is hydrogen, hydroxy, $C_{1-7}alkoxy$, -OR⁸ or -NR⁸R⁹ (wherein R⁸ is a group -Y¹R¹⁰ (wherein Y¹ is a direct bond, -C(O)-, -C(S)-, -S-, -C(O)O-, -C(O)NR¹¹-, -SO₂- or -SO₂NR¹²- (wherein R¹¹ and R¹², which may be the same or different, each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and R¹⁰ is selected from one of the following nine groups:

1) hydrogen, C_{1.7}alkyl, C_{3.7}cycloalkyl, C_{1.4}alkylY⁸C_{1.4}alkyl wherein Y⁸ is as defined herein, or phenyl.

(which alkyl, cycloalkyl, alkylY⁸alkyl or phenyl group may bear one or more substituents selected from:

halogeno, amino, $C_{1,4}$ alkylamino, di($C_{1,4}$ alkyl)amino, hydroxy, carboxy, carbamoyl, $C_{1,4}$ alkoxy, $C_{1,4}$ alkylsulphanyl, $C_{1,4}$ alkylsulphonyl, $C_{1,4}$ alkoxycarbonylamino, $C_{1,4}$ alkanoyl, phenyl, nitro, sulphate, phosphate,

Z¹ (wherein Z¹ represents a 5-6 membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, $C_{1,4}$ alkyl, $C_{1,4}$ hydroxyalkyl, $C_{1,4}$ alkoxy, $C_{1,4}$ aminoalkyl, $C_{1,7}$ alkanoyl, cyano $C_{1,4}$ alkyl, $C_{1,4}$ alkoxy $C_{1,4}$ alkyl, $C_{1,4}$ alkylsulphonyl $C_{1,4}$ alkyl and Z^2 (wherein Z^2 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

10

oxo, hydroxy, halogeno, C_{1-1} alkyl, C_{1-1} hydroxyalkyl, C_{1-1} alkoxy, C_{1-1} aminoalkyl, C_{1-7} alkanoyl, cyano C_{1-1} alkyl, C_{1-1} alkyl and C_{1-1} alkylsulphonyl C_{1-1} alkyl),

C1.4alkylZ1 (wherein Z1 is as defined herein), and

- a group -Y²R¹³ (wherein Y² is -NR¹⁴C(O)- or -O-C(O)- (wherein R¹⁴ represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and R¹³ is C_{1.7}alkyl, C_{3.7}cycloalkyl or a group R¹⁵ wherein R¹⁵ is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C_{1.4}alkyl, C_{1.4}haloalkyl, C_{1.4}alkoxy, C_{1.4}hydroxyalkyl, C_{1.4}aminoalkyl, C_{1.4}alkylamino, C_{1.4}hydroxyalkoxy, carboxy, cyano, -CONR¹⁶R¹⁷ and -NR¹⁸COR¹⁹ (wherein R¹⁶, R¹⁷, R¹⁸ and R¹⁹, which may be the same or different, each represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC₂.

 3alkyl)));
- 15 2) R¹⁵ wherein R¹⁵ is as defined herein;
 - 3) C₂₋₇alkenylR¹⁵ (wherein R¹⁵ is as defined herein);
 - 4) C_{3.7}alkynylR¹⁵ (wherein R¹⁵ is as defined herein));
 - 5) Z' (wherein Z' is as defined herein);
 - 6) C₁₋₇alkylZ' (wherein Z' is as defined herein);
- 7) C₁₋₇alkylY⁸Z¹ (wherein Z¹ is as defined herein and Y⁸ is -C(O)-, -NR⁵⁹C(O)-, -NR⁵⁹C(O)C₁₋₄alkyl-, -C(O)NR⁶⁰- or -C(O)NR⁶⁰C₁₋₄alkyl-, (wherein R⁵⁹ and R⁶⁰, which may be the same or different, each represents hydrogen, C₁₋₃alkyl, C₁₋₃hydroxyalkyl or C₁₋₃alkoxyC₂₋₃alkyl));

 8) (C₁₋₇alkyl)_cY⁹Z³ (wherein c is 0 or 1, Z³ is an amino acid group and Y⁹ is a direct bond, -
 - C(O)- or -NR⁶¹- (wherein R⁶¹ is hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl)); and
- 9) C_{1.7}alkylR¹⁵ (wherein R¹⁵ is as defined herein);
 and R⁹ is hydrogen, C_{1.7}alkyl or C_{3.7}cycloalkyl, which alkyl or cycloalkyl group may bear one or more substituents selected from C_{1.4}alkoxy and phenyl);
 R¹, R² and R³ are each independently
 - hvdrogen, PO₃H₂, sulphate, C₃₋₇cycloalkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₁₋₇alkanoyl, a group
- R²⁰ $C_{1.7}$ alkyl (wherein R²⁰ is phenyl which may bear one or more substituents selected from $C_{1.4}$ alkyl, $C_{1.4}$ alkoxy, $C_{1.4}$ aminoalkyl and $C_{1.4}$ hydroxyalkoxy), $C_{1.7}$ alkyl or $C_{1.7}$ alkylsulphonyl (which alkyl or alkylsulphonyl group may bear one or more substituents selected from:

10

15

20

25

halogeno, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, hydroxy, C₁₋₄alkoxy, C₁.

4alkylsulphanyl, C₁₋₄alkylsulphonyl, C₁₋₄alkoxycarbonylamino, C₁₋₄alkanoyl, carboxy, phenyl, nitro, sulphate, phosphate and a group -Y²R²¹ (wherein Y² is -NR²²C(O)- or -O-C(O)- (wherein R²² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²¹ is C₁.

7alkyl, C₃₋₇cycloalkyl or a group R²³ wherein R²³ is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁.

4hydroxyalkoxy, carboxy, cyano, -CONR²⁴R²⁵ and -NR²⁶COR²⁷ (wherein R²⁴, R²⁵, R²⁶ and R²⁷, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁.

3alkoxyC₂₋₃alkyl)));

with the proviso that at least two of R^1 , R^2 and R^3 are $C_{1.7}$ alkyl; R^4 is

hydrogen, cyano, halogeno, nitro, amino, hydroxy, C₁₋₇alkoxy, C₁₋₇thioalkoxy, C₁₋₇alkanoyl or C₁₋₇alkyl,

(which alkyl group may bear one or more substituents selected from: halogeno, amino, $C_{1,4}$ alkylamino, di($C_{1,4}$ alkyl)amino, hydroxy, $C_{1,4}$ alkoxy, $C_{1,4}$ alkoxy, $C_{1,4}$ alkylsulphanyl, $C_{1,4}$ alkylsulphonyl, $C_{1,4}$ alkoxycarbonylamino, $C_{1,4}$ alkanoyl, carboxy, phenyl, nitro, sulphate, phosphate and a group -Y³R²⁸ (wherein Y³ is -NR²⁹C(O)- or -O-C(O)- (wherein R²⁹ represents hydrogen, $C_{1,3}$ alkyl or $C_{1,3}$ alkoxy $C_{2,3}$ alkyl) and R^{28} is $C_{1,4}$ alkyl, $C_{3,4}$ cycloalkyl or a group R^{30} wherein R^{30} is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, $C_{1,4}$ alkyl, $C_{1,4}$ hydroxyalkyl, $C_{1,4}$ aminoalkyl, $C_{1,4}$ alkylamino, $C_{1,4}$ hydroxyalkoxy, carboxy, cyano, -CONR³¹R³² and -NR³¹COR³² (wherein R³¹, R³², R³³ and R³⁴, which may be the same or different, each represents hydrogen, $C_{1,3}$ alkyl or $C_{1,3}$ alkoxy $C_{2,3}$ alkyl)));

R⁵ and R⁶ are each independently selected from hydrogen, -OPO₃H₂, phosphonate, cyano, halogeno, nitro, amino, carboxy, carbamoyl, hydroxy, C_{1.7}alkoxy, C_{1.7}alkanoyl, C_{1.7}thioalkoxy, C_{1.7}alkyl.

10

20

25

30

(which alkyl group may bear one or more substituents selected from: halogeno, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, hydroxy, C₁₋₄alkoxy, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphonyl, C₁₋₄alkoxycarbonylamino, C₁₋₄alkanoyl, carboxy, phenyl, sulphate, phosphate and a group -Y³R²⁸ (wherein Y³ is -NR²⁹C(O)- or -O-C(O)- (wherein R²⁹ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁸ is C₁₋₇alkyl, C₃₋₇cycloalkyl or a group R³⁰ wherein R³⁰ is a phenyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, cyano, -CONR³¹R³² and -NR³¹COR³² (wherein R³¹, R³², R³³ and R³⁴, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁₋₃alkyl)), and

a group -Y4R35

(wherein Y⁴ is -C(O)-, -OC(O)-, -O-, -SO-, -SO₂-, -OSO₂-, -NR³⁶-, -C₁₋₄alkylNR³⁶-, -C₁.

4alkylC(O)-, -NR³⁷C(O)-, -OC(O)O-, -C(O)NR³⁸- or -NR³⁹C(O)O- (wherein R³⁶, R³⁷, R³⁸

and R³⁹, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁.

3alkoxyC₂₋₃alkyl) and

 R^{35} is a sugar moiety, a mono-peptide, a di-peptide, a tri-peptide, a tetra-peptide, sulphate, hydroxy, amino, $C_{1.7}$ alkyl, $C_{1.7}$ alkoxy, $C_{1.7}$ alkanoyl, $C_{1.7}$ alkylamino, di($C_{1.7}$ alkyl)amino, amino $C_{1.7}$ alkylamino, $C_{1.7}$ alkylphosphonate, $C_{1.7}$ alkylphosphonate, $C_{1.7}$ alkylcarbamoyl $C_{1.7}$ alkyl,

(which alkyl, alkoxy, alkanoyl, alkylamino, dialkylamino, aminoalkylamino, alkylaminoalkylamino, alkanoylaminoalkyl, dialkylaminoalkylamino, alkylphosphate, alkylphosphonate or alkylcarbamoylalkyl, may bear one or more substituents selected from:

halogeno, amino, $C_{1,4}$ alkylamino, di($C_{1,4}$ alkyl)amino, hydroxy, $C_{1,4}$ hydroxyalkyl, $C_{1,4}$ alkoxy, $C_{1,4}$ alkylsulphanyl, $C_{1,4}$ alkylsulphonyl, $C_{1,4}$ alkoxycarbonylamino, $C_{1,4}$ alkanoyl, carboxy, phenyl, nitro, sulphate, phosphate and a group -Y⁵R⁴⁰ (wherein Y⁵ is -NR⁴¹C(O)-, -C(O)NR⁴²-, -C(O)-O- or -O-C(O)- (wherein R⁴¹ and R⁴² which may be the same or different each represents hydrogen, $C_{1,4}$ alkyl or $C_{1,3}$ alkoxy $C_{2,3}$ alkyl) and

10

15

20



R⁴⁰ is C₁₋₇alkyl, C₃₋₇cycloalkyl, carboxyC₁₋₇alkyl or a group R⁴³ wherein R⁴³ is a phenyl group, a benzyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl, benzyl or aromatic heterocyclic group may bear one or more substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, cyano, -CONR⁴⁴R⁴⁵ and -NR⁴⁶COR⁴⁷ (wherein R⁴⁴, R⁴⁵, R⁴⁶ and R⁴⁷, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂.

R⁴⁸ (wherein R⁴⁸ is a phenyl group, a benzyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl, benzyl or aromatic heterocyclic group may bear one or more substituents selected from

hydroxy, nitro, halogeno, amino, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, di(C_{1-4} alkyl)amino C_{1-4} alkyl, di(C_{1-4} alkyl)amino C_{1-4} alkyl, di(C_{1-4} aminoalkyl)amino C_{1-4} alkyl, C_{1-4} hydroxyalkoxy, carboxy, C_{1-4} carboxyalkyl, phenyl, cyano, -CONR⁴⁹R⁵⁰, -NR⁵¹COR⁵² (wherein R⁴⁹, R⁵⁰, R⁵¹ and R⁵², which may be the same or different, each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and C_{1-4} alkylR⁵³ (wherein R⁵³ is as defined herein),

C_{1.7}alkylR⁴⁸ (wherein R⁴⁸ is as defined herein),

R⁵³ (wherein R⁵³ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄carboxyalkyl, C₁.

4aminoalkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl and R⁵⁴ (wherein R⁵⁴ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, C_{14} alkyl, C_{14} hydroxyalkyl, C_{14} alkoxy, C_{14} alkoxy C_{15} alkyl and C_{14} alkylsulphonyl C_{14} alkyl)), or

 $(CH_2)_a Y^6 (CH_2)_b R^{53}$ (wherein R^{53} is as defined herein, a is 0, or an integer 1-4, b is 0 or an integer 1-4 and Y^6 represents a direct bond, -O-, -C(O)-, -NR⁵⁵-, -NR⁵⁶C(O)- or -

25

20

30

C(O)NR⁵⁷- (wherein R⁵⁵, R⁵⁶, and R⁵⁷, which may be the same or different, each represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and wherein one or more of the (CH₂)_a or (CH₂)_b groups may bear one or more substituents selected from hydroxy, amino and halogeno));

- with the proviso that R⁵ is not hydroxy, alkoxy, substituted alkoxy (wherein R⁵ is Y⁴R³⁵ and Y⁴ is -O- and R³⁵ is C_{1.7}alkyl bearing one or more substituents selected from the list given herein), -OPO₃H₂, -O-C_{1.7}alkanoyl or benzyloxy; with the further proviso that at least one of R⁵ or R⁶ is a group -Y⁴R³⁵ (wherein Y⁴ and R³⁵ are as defined herein) but with the further provisos
- that when R⁵ is -Y⁴R³⁵ and R⁶ is hydrogen, hydroxy, methoxy or methoxycarbonyl, -Y⁴R³⁵ is not selected from cases wherein:

Y⁴ is -C(O)-, -OC(O)-, -O-, -SO-, -OSO₂-, -NR³⁶-, -NR³⁷C(O)- or -C(O)NR³⁸- (wherein R³⁶, R³⁷ and R³⁸, which may be the same or different, each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R³⁵ is

a glycine, valine or lysine group, a dipeptide of glycine and valine groups, C_{1.7}alkyl, C_{1.7}alkoxy, C_{1.7}alkanoyl,

(which alkyl, alkoxy or alkanoyl may bear one or more substituents selected from: halogeno, hydroxy, and a group $-Y^5R^{40}$ (wherein Y^5 is -O-C(O)- and R^{40} is $C_{1.7}$ alkyl)), or

 R^{48} (wherein R^{48} is a tetrazolyl group (which may or may not be substituted as herein defined), a phenyl group or a benzyl group which phenyl or benzyl group may bear one or more substituents selected from C_{14} alkyl); and

that when R⁶ is -Y⁴R³⁵ and R⁵ is hydrogen, hydroxy, methoxy or methoxycarbonyl, -Y⁴R³⁵ is not selected from cases wherein:

25 Y^4 is -C(O)-, -O- or -OSO₂- and R^{35} is

C₁₋₇alkyl, C₁₋₇alkoxy

(which alkyl, alkoxy or alkanoyl may bear one or more substituents selected from: halogeno),

 R^{48} (wherein R^{48} is a benzyl group which benzyl group may bear one or more substituents selected from C_{14} alkyl), or

R⁵³ (wherein R⁵³ is piperidinyl);

or a salt thereof.

10

20

25

- 3. The use of a compound of the formula IIa as defined in claim 2, or a salt thereof, a pharmaceutically acceptable salt thereof, a solvate or hydrate thereof, or a prodrug thereof, in the manufacture of a medicament for use in the production of a vascular damaging effect in warm-blooded animals such as humans.
- 4. A compound according to claim 2 wherein X is -CH(R^7)- wherein R^7 is -OR⁸ or -NR⁸R⁹ (wherein R⁸ is a group -Y¹R¹⁰ (wherein Y¹ is -C(O)-, -C(O)O- or -C(O)NR¹¹- (wherein R¹¹ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁰ is as defined in claim 2) and R⁹ is as defined in claim 2).
- 5. A compound according to claim 2 or claim 4 wherein R^1 , R^2 and R^3 are each methyl.
- 6. A compound according to any one of claims 2, 4 or 5 wherein R⁴ is hydrogen.
- 7. A compound according to any one of claims 2, 4, 5 or 6 wherein R⁶ is hydrogen, halogeno, amino, carboxy, hydroxy, C_{1.7}alkoxy or a group Y⁴R³⁵ (wherein Y⁴ is -C(O)-, -O- or -OSO₂- and R³⁵ is C_{1.7}alkyl, C_{1.7}alkoxy (which alkyl or alkoxy may bear one or more substituents selected from halogeno), R⁴⁸ (wherein R⁴⁸ is a benzyl group) or R⁵³ (wherein R⁵¹ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms selected independently from O, S and N)).
- 8. A compound according to any one of claims 2, 4, 5, 6 or 7 wherein R⁶ is hydrogen, C(O)OCH₃ or methoxy.
- 9. A compound according to any one of claims 2, 4, 5, 6, 7 or 8 wherein R⁵ is hydrogen, halogeno, amino, carboxy, carbamoyl, C₁₋₇alkanoyl, C₁₋₇thioalkoxy, or a group -Y⁴R³⁵

(wherein Y⁴ is -C(O)-, -OC(O)-, -O-, -SO-, -OSO₂-, -NR³⁶-, -NR³⁷C(O)- or -C(O)NR³⁸
(wherein R³⁶, R³⁷ and R³⁸, which may be the same or different, each represents hydrogen,

C_{1,3}alkyl or C_{1,3}alko×yC_{2,3}alkyl) and

Cont

R³⁵ is a sugar moiety, a mono-peptide, a di-peptide, a tri-peptide, a tetra-peptide, C_{1.7}alkyl, C_{1.7}alkanoyl, C_{1.7}alkanoylaminoC_{1.7}alkyl,

(which alkyl, alkoxy, alkanoyl, alkanoylaminoalkyl may bear one or more substituents selected from:

halogeno, amino, hydroxy, carboxy, and a group $-Y^5R^{40}$ (wherein Y^5 is -C(O)-O- or -C(O) and R^{40} is C_{1-7} alkyl or a group R^{43} wherein R^{43} is a benzyl group),

R⁴⁸ (wherein R⁴⁸ is a phenyl group, a benzyl group or a 5-10-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-4 heteroatoms selected independently from O, N and S, which phenyl, benzyl or aromatic heterocyclic group may bear one or more substituents selected from

hydroxy, fluoro, amino, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino C_{1-4} alkyl, di(C_{1-4} hydroxyalkyl)amino C_{1-4} alkyl, di(C_{1-4} hydroxyalkyl)amino C_{1-4} alkyl, C_{1-4} hydroxyalkoxy, carboxy, C_{1-4} carboxyalkyl, cyano, -CONR⁴⁹R⁵⁰, NR⁵¹COR⁵² (wherein R⁴⁹, R⁵⁰, R⁵¹ and R⁵², which may be the same or different, each represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and C_{1-4} alkylR⁵³ (wherein R⁵³ is as defined herein),

C₁₋₇alkylR⁴⁸ (wherein R⁴⁸ is as defined herein),

R⁵³ (wherein R⁵³ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, fluoro, chloro, Chalkyl, Chahydroxyalkyl, Chalkoxy, Chacarboxyalkyl, Chaminoalkyl, di(Chalkyl)aminoChalkyl, Chalkyl, Chalkyl, Chalkyl, Chalkyl, ChalkylsulphonylChalkyl and R⁵⁴ (wherein R⁵⁴ is a 5-6 membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from

oxo, hydroxy, halogeno, $C_{1\rightarrow}$ alkyl, $C_{1\rightarrow}$ hydroxyalkyl, $C_{1\rightarrow}$ alkoxy, $C_{1\rightarrow}$ alkoxy $C_{1\rightarrow}$ alkyl and $C_{1\rightarrow}$ alkylsulphonyl $C_{1\rightarrow}$ alkyl)), or

 $(CH_2)_a Y^6 (CH_2)_b R^{53}$ (wherein R^{53} is as defined herein, a is 0, or an integer 1-4, b is 0 or an integer 1-4 and Y^6 represents a direct bond, -O-, -(O)-, -NR⁵⁵-, -NR⁵⁶C(O)- or -

C(O)NR⁵⁷- (wherein R⁵⁵, R⁵⁶, and R⁵⁷, which may be the same or different, each represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl), and wherein one or more of the (CH₂)_a or

15

10

5

20

25

Cott

5

(CH₂)_b groups may bear one or more substituents selected from hydroxy, amino and halogono));

with the proviso that R^5 is not alkoxy, substituted alkoxy (wherein R^5 is Y^4R^{35} and Y^4 is -O-and R^{35} is $C_{1.7}$ alkyl bearing one or more substituents selected from the list given herein), -O- $C_{1.7}$ alkanoyl or benzyloxy.

- 10. A compound according to claim_2 selected from:
- (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-{[(2R)-2,6-diaminohexanoyl]amino}propanoate,
- 10 (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5*H*-dibenzo[*a*,*c*]cyclohepten-3-yl 3-[(2-aminoacetyl)amino]propanoate,
 - N-([(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl]oxymethyl)-2-morpholinoacetamide,
 - (2S,3S,4S,5R,6R)-6-{[(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5*H*-
- dibenzo[a,c]cyclohepten-3-yl]oxy}-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-carboxylic acid, N-[(5S)-3-(4-{4-methylpiperazin-1-ylmethyl}phenylcarbonyloxy)-9,10,11-trimethoxy-6,7-dibydro-5*H*-dibenzo[a,c]cyclohepten-5-yl]acetamide,
 - $N-\{(5S)-3-(4-\{\text{morpholinomethyl}\}\text{phenylcarbonyloxy})-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide,$
- 20 (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5*H*-dibenzo[*a*,*c*]cyclohepten-3-yl 3-[4-methylpiperazin-1-ylcarbonyl]propanoate,
 - $5-[\{(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl\}oxycarbonyl]$ pentanoic acid,
 - 4-(3-[(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-
- 25 yl]oxy-3-oxopropyl)benzoic acid and
 - (2S)-N-[(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl]-2-amino-3-hydroxypropanamide,
 - and salts thereof.
- 30 11. A compound according to claim 2 selected from N-[(5S)-3-(4-{4-methylpiperazin-1-ylmethyl}phenylcarbonyloxy)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide and

The first term from the first term to the first

15

(2S)-N-[(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl]-2-amino-3-hydroxypropanamide, and salts thereof.

- 12. A compound according to claim 2 selected from (2S)-N-[(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl]-2-amino-5-[(2-nitroethanimidoyl)amino]pentanamide and salts thereof.
- 10 13. A process for the manufacture of a compound of formula IIa as defined in claim 2 which comprises:
 - (a) for the preparation of compounds of formula IIa and salts thereof in which R⁵ or R⁶ is a group Y⁴R³⁵ (wherein R³⁵ is as defined in claim 2 and Y⁴ is a group -OC(O)- or -NHC(O)-), the reaction of a compound of formula III or IV:

$$R^{2}$$
 R^{2}
 R^{1}
 R^{2}
 R^{4}
 R^{6}
 Y^{7} -H
 R^{6}
 Y^{7} -H
 R^{7}
 R^{5}
 R^{1}
 R^{2}
 R^{1}
 R^{2}
 R^{1}
 R^{2}
 R^{1}
 R^{2}
 R^{1}
 R^{2}
 R^{2}
 R^{3}
 R^{2}
 R^{2}
 R^{4}
 R^{5}

(wherein X, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 are as defined in claim 2 and Y^7 is -O- or -NH-), by acylation or coupling reactions;

- 20 (b) for the preparation of compounds of formula IIa and salts thereof in which R⁵ or R⁶ is a group Y⁴R³⁵ (wherein R³⁵ is C_{1.7}alkoxy which may be substituted as defined in claim 2 and Y⁴ is a group -OC(O)- or -NHC(O)-), the reaction of a compound of formula III and IV, by acylation reactions;
- (c) for the preparation of compounds of formula IIa and salts thereof in which R⁵ or R⁶ is a

 25 group Y⁴R³⁵ (wherein R³⁵ is aminoC_{1.7}alkylamino, C_{1.7}alkylaminoC_{1.7}alkylamino, di(C_{1.7}alkylaminoC_{1.7}alkylaminoC_{1.7}alkylamino and may be substituted as defined in claim 2, or is R⁵³ (wherein

10

R⁵³ is as defined in claim 2) and Y⁴ is a group -OC(0)- or -NHC(0)-), can be prepared by the reaction of a compound of formula III or IV, acylation reactions;

- (d) for the preparation of compounds of formula IIa and salts thereof in which R⁵ or R⁶ is a group Y⁴R³⁵ (wherein R³⁵ is a sugar moiety and Y⁴ is a group -O- or -NH-), the reaction of a compound of formula III or IV, glycosylation reactions;
- (e) for the preparation of compounds of formula IIa and salts thereof in which R^5 or R^6 is a group Y^4R^{35} (wherein R^{35} is sulphate and Y^4 is a group -O- or -NH-), the reaction of a compound of formula III or IV, by sulphonylation reactions;
- (f) for the preparation of compounds of formula IIa and salts thereof in which R⁵ or R⁶ is a group Y⁴R³⁵ (wherein R³⁵ is C₁₋₇alkylphosphate and may be substituted as defined in claim 2 and Y⁴ is a group -O- or -NH-), the reaction of a compound of formula III or IV, by phosphorylation reactions;
- (g) for the preparation of compounds of formula IIa and salts thereof in which R⁵ is amino the reaction of a carboxylic acid of formula V:

$$R^{2}$$
 R^{1}
 R^{6}
 R^{6}
 R^{1}
 R^{6}
 R^{1}

(V)

(wherein X, R¹, R², R³, R⁴ and R⁶ are as defined in claim 2) via Curtius rearrangement and hydrolysis; and

20 (h) for the preparation of compounds of formula IIa and salts thereof in which R⁵ or R⁶ is chloro the reaction of a compound of formula III or IV by the Sandmeyer reaction; and when a pharmaceutically acceptable salt of a compound of formula IIa is required, reaction of the compound obtained with an acid or base whereby to obtain the desired pharmaceutically acceptable salt.

- 14. A pharmaceutical composition which comprises as active ingredient a compound of formula IIa as defined in claim 2 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient or carrier.
- 5 15. A method for producing a vascular damaging effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula IIa or a pharmaceutically acceptable salt thereof as defined in claim 2.